Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.00M | 0.00 | 121.37M | 0.00 | 0.00 | Gross Profit |
1.00M | -189.00K | 63.77M | -55.00K | -63.00K | EBIT |
-22.41M | -25.71M | -57.60M | -29.05M | -19.14M | EBITDA |
-22.23M | -25.52M | -115.20M | -29.00M | -19.08M | Net Income Common Stockholders |
-19.98M | -20.84M | -54.23M | -27.47M | -8.14M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
31.25M | 50.53M | 69.23M | 94.97M | 34.57M | Total Assets |
35.00M | 54.69M | 73.03M | 97.01M | 36.00M | Total Debt |
137.00K | 305.00K | 485.00K | 714.00K | 624.00K | Net Debt |
-16.07M | -22.29M | -31.67M | -23.93M | -15.89M | Total Liabilities |
5.68M | 6.80M | 6.71M | 5.01M | 3.76M | Stockholders Equity |
29.57M | 48.15M | 66.58M | 92.25M | 32.50M |
Cash Flow | Free Cash Flow | |||
-19.36M | -20.03M | -21.45M | -22.30M | -8.84M | Operating Cash Flow |
-19.36M | -20.03M | -21.17M | -22.25M | -8.82M | Investing Cash Flow |
13.23M | 10.10M | 28.91M | -54.90M | -7.28M | Financing Cash Flow |
-206.00K | 385.00K | -224.00K | 85.28M | 18.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $20.59M | ― | -121.65% | ― | -0.71% | -169.29% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
43 Neutral | $21.81M | ― | -51.43% | ― | ― | 7.07% | |
38 Underperform | $19.23M | ― | 27.46% | ― | ― | 98.61% | |
35 Underperform | $25.73M | ― | -164.30% | ― | ― | 44.38% | |
33 Underperform | $22.26M | ― | -77.48% | ― | ― | 47.73% |
On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.